SK Bioscience, as early as this week’s deliberation result… Rising expectations
Korean pharmaceutical bio companies’ IPO challenges are expected to continue. It is interpreted as a strategy to raise the competitiveness of new drug candidates and technologies, and to attract financial resources to be invested in new research and development (R&D).
According to the industry on the 25th, this year, SK Bioscience, HK inno.N (formerly CJ Healthcare), Neo-Imuntech, and Voronoi were listed on the IPO waiting list.
The pharmaceutical biotechnology company that is receiving the most attention is SK Bioscience. SK Bioscience is a vaccine company that was divided physically by SK Chemicals in July 2018, and it develops and sells vaccines for influenza, shingles, and chickenpox.
In particular, regarding the Corona 19 vaccine, he was in charge of entering phase 1 clinical trials of’NBP2001′, which is being developed by itself, as well as consignment production (CMO) of a global pharmaceutical company.
On December 1 of last year, SK Biosciences submitted a preliminary application for IPO to the Korea Exchange. Since the results of the listing committee’s deliberation must be notified within 45 days after the application is received, the exchange is expected to produce results this week as early as possible. SK Bioscience aims to submit a stock report to the Financial Services Commission afterwards and enter securities (KOSPI) in the first half of the year.
HK inno.N is a pharmaceutical bio company that started as CJ CheilJedang’s pharmaceutical division in 1984 and was acquired by Kolmar Korea in 2018 after being launched as CJ Healthcare in 2014. The representative medicine is’K-Cap Tablet’, a drug for gastroesophageal reflux disease, the 30th domestic drug. HK inno.N is also engaged in H&B business such as hangover relief drink’Condition’, health functional food’Nutin’, and cosmetics’Klederma’.
HK inno.N selected Samsung Securities, Korea Investment & Securities, and JP Morgan as their managers, and is currently preparing to list on the KOSPI within this year. An official from HK inno.N said, “We plan to use the funds secured through IPO as a source of investment for major new drugs and bio R&D such as autoimmune diseases, non-alcoholic steatohepatitis, and anticancer.”
Neo-Imuntech is a pharmaceutical bio company that develops immune anticancer drugs, with Genexin being the largest shareholder. Neo-Imuntech passed the preliminary examination for technical special listing on the KOSDAQ market in December last year. Neoimmuntech plans to proceed with general subscription on the 5th to 8th of the same month after forecasting the demand on February 1st and 2nd.
Voronoi will re-challenge for listing on the KOSDAQ this year, two years after having been eliminated from the 2019 technology evaluation. Voronoi is particularly likely to be listed last year as it achieved a technology export of a candidate drug that selectively acts on mutant non-small cell lung cancer for about 720 billion won.
An official in the industry argued that “IPOs centered on companies that can create a definite source of revenue based on research possibilities and values are expected to be actively conducted.”
Copyright © Shin-A Ilbo Unauthorized reproduction and redistribution prohibited